MORE►
cancer drugs
Dr. Theodora Ross, president of the Cancer Prevention Initiative [Photo: CPI]
Dallas’ Cancer Prevention Initiative Announces $750K Matching Grant Challenge From Lyda Hill Philanthropies
by Sandra Engelland | Dec 10, 2025
Founded on the principle that prevention is the most powerful form of cure, CPI funds innovative research aimed at intercepting cancer before it begins. The organization said it focuses on inherited cancers where a "genetic predisposition provides a clear target for early intervention—and uses this lens to unlock insights that can lead to the prevention of all cancers."
by David Seeley |
Aug 6, 2024
A study co-led by UTSW's Jin Huk Choi, Ph.D., and Nobel Prize winner Bruce Beutler, M.D., found that targeting a gene-produced protein called ZFP574 "reduced the amount of malignant B cells by as much as 92%." Their findings could lead to new treatments for leukemias and lymphomas—and potentially other cancers, too.
MORE►
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-based Celanese Corporation has announced a collaboration with Alessa Therapeutics for developing a new oncology drug product, by utilizing the Celanese VitalDose EVA drug delivery platform. "Our new collaboration with Alessa Therapeutics underscores our commitment to optimize therapeutics through drug delivery innovation for oncology patients,” said Karen Chen, global business strategy leader for oncology at
Celanese.
MORE►
by David Seeley |
Jan 30, 2023
Dallas' Mark Cuban Cost Plus Drug Company announced a collaboration today with Houston-based OncoPower that will enable cancer patients using OncoPower to look up pricing and order less expensive medications.
OncoPower offers a free app and website with a social media-style format where patients can access professionals including dietitians and behavioral therapists, as well as cancer education and meditation content, tools for treatment adherence, and clinical trial mapping.
MORE►
